<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Proc Natl Acad Sci U S A</journal-id>
<journal-id journal-id-type="iso-abbrev">Proc. Natl. Acad. Sci. U.S.A</journal-id>
<journal-id journal-id-type="hwp">pnas</journal-id>
<journal-id journal-id-type="pmc">pnas</journal-id>
<journal-id journal-id-type="publisher-id">PNAS</journal-id>
<journal-title-group>
<journal-title>Proceedings of the National Academy of Sciences of the United States of America</journal-title>
</journal-title-group>
<issn pub-type="ppub">0027-8424</issn>
<issn pub-type="epub">1091-6490</issn>
<publisher>
<publisher-name>National Academy of Sciences</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26627235</article-id>
<article-id pub-id-type="pmc">4672772</article-id>
<article-id pub-id-type="publisher-id">201514657</article-id>
<article-id pub-id-type="doi">10.1073/pnas.1514657112</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Biological Sciences</subject>
<subj-group>
<subject>Applied Biological Sciences</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Compromising the phosphodependent regulation of the GABA<sub>A</sub>R β3 subunit reproduces the core phenotypes of autism spectrum disorders</article-title>
<alt-title alt-title-type="short">GABAAR phosphorylation and autism</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Vien</surname>
<given-names>Thuy N.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Modgil</surname>
<given-names>Amit</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Abramian</surname>
<given-names>Armen M.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jurd</surname>
<given-names>Rachel</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Walker</surname>
<given-names>Joshua</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brandon</surname>
<given-names>Nicholas J.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Terunuma</surname>
<given-names>Miho</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>c</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rudolph</surname>
<given-names>Uwe</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>d</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Maguire</surname>
<given-names>Jamie</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Davies</surname>
<given-names>Paul A.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Moss</surname>
<given-names>Stephen J.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>e</sup>
</xref>
<xref ref-type="corresp" rid="cor1">
<sup>1</sup>
</xref>
</contrib>
<aff id="aff1"><sup>a</sup>Department of Neuroscience, <institution>Tufts University School of Medicine</institution>, Boston, <addr-line>MA</addr-line> 02111;</aff>
<aff id="aff2"><sup>b</sup><institution>AstraZeneca Neuroscience iMed</institution>, Cambridge, <addr-line>MA</addr-line> 02139;</aff>
<aff id="aff3"><sup>c</sup>Department of Cell Physiology and Pharmacology, <institution>University of Leicester</institution>, Leicester LE1 9HN, <country>United Kingdom</country>;</aff>
<aff id="aff4"><sup>d</sup>Laboratory of Genetic Neuropharmacology, McLean Hospital, and Department of Psychiatry, <institution>Harvard Medical School</institution>, Belmont, <addr-line>MA</addr-line> 02478;</aff>
<aff id="aff5"><sup>e</sup>Department of Neuroscience, Physiology, and Pharmacology, <institution>University College</institution>, London WC1E 6BT, <country>United Kingdom</country></aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><sup>1</sup>To whom correspondence should be addressed. Email: <email>stephen.moss@tufts.edu</email>.</corresp>
<fn fn-type="edited-by">
<p>Edited by Richard L. Huganir, The Johns Hopkins University School of Medicine, Baltimore, MD, and approved October 22, 2015 (received for review July 24, 2015)</p>
</fn>
<fn fn-type="con">
<p>Author contributions: T.N.V., A.M., A.M.A., R.J., J.W., M.T., U.R., and J.M. designed research; T.N.V., A.M., A.M.A., R.J., J.W., N.J.B., M.T., U.R., and J.M. performed research; A.M.A., M.T., and U.R. contributed new reagents/analytic tools; T.N.V., A.M., A.M.A., R.J., J.W., N.J.B., M.T., U.R., J.M., and P.A.D. analyzed data; and T.N.V., N.J.B., U.R., J.M., P.A.D., and S.J.M. wrote the paper.</p>
</fn>
<fn fn-type="conflict">
<p>Conflict of interest statement: S.J.M. serves as a consultant for AstraZeneca and SAGE Therapeutics, relationships that are regulated by Tufts University and do not have an impact on this study.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>1</day>
<month>12</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="epub">
<day>16</day>
<month>11</month>
<year>2015</year>
</pub-date>
<volume>112</volume>
<issue>48</issue>
<fpage>14805</fpage>
<lpage>14810</lpage>
<self-uri xlink:href="pnas.201514657.pdf" xlink:title="pdf"></self-uri>
<abstract abstract-type="executive-summary">
<title>Significance</title>
<p>Alterations in the efficacy of neuronal inhibition mediated by GABA<sub>A</sub> receptors (GABA<sub>A</sub>Rs) containing β3 subunits are continually implicated in autism spectrum disorders (ASDs). In vitro, the plasma membrane stability of GABA<sub>A</sub>Rs is potentiated via phosphorylation of serine residues 408 and 409 (S408/9) in the β3 subunit, an effect that is mimicked by their mutation to alanines. Here, we created a mouse in which S408/9 have been mutated to alanines (S408/9A). S408/9A mice exhibited altered dendritic spine structure, increased repetitive behavior, decreased social interaction, and an epileptic phenotype. Thus, mutation of S408/9 reproduces the core deficits seen in humans with ASDs. Collectively, our results suggest that alterations in phosphorylation and/or activity of β3-containing GABA<sub>A</sub>Rs may directly contribute to the pathophysiology of ASDs.</p>
</abstract>
<abstract>
<p>Alterations in the efficacy of neuronal inhibition mediated by GABA<sub>A</sub> receptors (GABA<sub>A</sub>Rs) containing β3 subunits are continually implicated in autism spectrum disorders (ASDs). In vitro, the plasma membrane stability of GABA<sub>A</sub>Rs is potentiated via phosphorylation of serine residues 408 and 409 (S408/9) in the β3 subunit, an effect that is mimicked by their mutation to alanines. To assess if modifications in β3 subunit expression contribute to ASDs, we have created a mouse in which S408/9 have been mutated to alanines (S408/9A). S408/9A homozygotes exhibited increased phasic, but decreased tonic, inhibition, events that correlated with alterations in the membrane stability and synaptic accumulation of the receptor subtypes that mediate these distinct forms of inhibition. S408/9A mice exhibited alterations in dendritic spine structure, increased repetitive behavior, and decreased social interaction, hallmarks of ASDs. ASDs are frequently comorbid with epilepsy, and consistent with this comorbidity, S408/9A mice exhibited a marked increase in sensitivity to seizures induced by the convulsant kainic acid. To assess the relevance of our studies using S408/9A mice for the pathophysiology of ASDs, we measured S408/9 phosphorylation in <italic>Fmr1</italic> KO mice, a model of fragile X syndrome, the most common monogenetic cause of ASDs. Phosphorylation of S408/9 was selectively and significantly enhanced in <italic>Fmr1</italic> KO mice. Collectively, our results suggest that alterations in phosphorylation and/or activity of β3-containing GABA<sub>A</sub>Rs may directly contribute to the pathophysiology of ASDs.</p>
</abstract>
<kwd-group>
<kwd>GABA receptor</kwd>
<kwd>phosphorylation</kwd>
<kwd>autism spectrum disorder</kwd>
<kwd>tonic inhibition</kwd>
<kwd>phasic inhibition</kwd>
</kwd-group>
<funding-group>
<award-group id="gs1">
<funding-source id="sp1">HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS)<named-content content-type="funder-id">100000065</named-content></funding-source>
<award-id rid="sp1">NS051195</award-id>
<award-id rid="sp1">NS056359</award-id>
<award-id rid="sp1">NS081735</award-id>
<award-id rid="sp1">R21NS080064</award-id>
<award-id rid="sp1">NS087662 and NS073574</award-id>
</award-group>
<award-group id="gs2">
<funding-source id="sp2">HHS | NIH | National Institute of Mental Health (NIMH)<named-content content-type="funder-id">100000025</named-content></funding-source>
<award-id rid="sp2">MH097446 R01MH080006</award-id>
</award-group>
<award-group id="gs3">
<funding-source id="sp3">DOD | Congressionally Directed Medical Research Programs (CDMRP)<named-content content-type="funder-id">100000090</named-content></funding-source>
<award-id rid="sp3">AR140209</award-id>
</award-group>
<award-group id="gs4">
<funding-source id="sp4">Simons Foundation (SF)<named-content content-type="funder-id">100000893</named-content></funding-source>
<award-id rid="sp4">206026</award-id>
</award-group>
</funding-group>
<counts>
<page-count count="6"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>